Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review

Expert Review of Clinical Pharmacology

Volumn 9, Issue 6, 2016, Pages 821-829

  Weingartner V ^a   Dargatz, N ^a   Weber, C ^a   Mueller, D ^a   Stock, S ^a   Voltz, R ^a   Gaertner, J ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

advanced cancer; decision making; early integration; early palliative care; oncology; palliative care; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS; OUTCOME ASSESSMENT; PANCREAS CANCER; PATIENT REPORTED OUTCOME; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; DECISION MAKING; METHODOLOGY; NEOPLASMS; PATHOLOGY; PATIENT-REPORTED OUTCOME; PROCEDURES; SURVIVAL RATE;

DECISION MAKING; HUMANS; NEOPLASMS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL RATE;

EID: 84964053710     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1164595     Document Type: Review

References (35)

1. E.Basch, A.P.Abernethy, C.D.Mullins, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol Off Am Soc Clin Oncol. 4249–4255;30(34):2012.•• Key recommendations include the assessment of patient-reported symptoms as well as health-related quality of life in all prospective clinical cancer trials. Advice is given how to identify symptoms relevant to a particular study population, how to prove validity and reliability of PRO measures used among others.
2. C.Brettschneider, D.Lühmann, H.Raspe Informative value of patient reported outcomes (PRO) in health technology assessment (HTA). GMS Health Technol Assess. 2011;7:Doc01.
3. M.Calvert, J.Blazeby, D.G.Altman, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–822.•• Presenting the checklist for the CONSORT standard of reporting PRO outcomes of clinical trials. Helpful and interesting article for authors, reviewers and interested researchers.
4. M.Brundage, B.Bass, J.Davidson, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2011;20(5):653–664.
5. J.Gaertner, V.Weingärtner, S.Lange, et al. The role of end-of-life issues in the design and reporting of cancer clinical trials: a structured literature review. PloS One. 2015;10(9):e0136640.• Previous work assessing advanced cancer trials and leading to the idea for current review. The main finding of this review was the fact that the EoL situation of patients with advanced cancer is still hardly considered in clinical trials. Suggestions for improving standards for study design and reporting are presented.
6. I.J.Higginson, B.Gomes, N.Calanzani, et al. Priorities for treatment, care and information if faced with serious illness: a comparative population-based survey in seven European countries. Palliat Med. 2014;28(2):101–110.• Presenting the results of an interesting survey among European citizens with the main result highlighting the relevance of quality of life as the major therapeutic goal next to survival.
7. World Health Organization (WHO). WHO definition of palliative care [Internet]. 2013 [Zugriff: 2013 Aug22]. Available from: http://www.who.int/cancer/palliative/definition/en/.
8. A.C.Society. Goals of the American Cancer Society [Internet]. (2015). [Zugriff: 2013 Aug21]. Available from: http://relay.acsevents.org/site/DocServer/ACS%20Mission%20Statement-2015%20Goals.pdf
9. Food and Drug Administration UDoHaHS, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims [Internet]. December 2009 [Zugriff: 2013 Aug 21]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.
10. National Institutes of Health - Department of Health and Human Services. Common fund strategic planning report 2009 [Internet]. January 01, 2011 [Zugriff: 2013 Aug 21]. Available from: http://commonfund.nih.gov/about-cfspr2009.aspx.
11. C.J.Evans, H.Benalia, N.J.Preston, et al. The selection and use of outcome measures in palliative and end-of-life care research: the MORECare international consensus workshop. J Pain Symptom Manage. 2013;46(6):925–937.
12. A.Liberati, D.G.Altman, J.Tetzlaff, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94.
13. D.Moher, A.Liberati, J.Tetzlaff, et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64.
14. K.Johnston. What are surrogate outcome measures and why do they fail in clinical research?. Neuroepidemiology. 1999;18(4):167–173.
15. L.Turner, L.Shamseer, D.G.Altman, et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60.
16. A.R.Jadad, R.A.Moore, D.Carroll, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12.
17. D.Moher, S.Hopewell, K.F.Schulz, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg Lond Engl. 2012;10(1):28–55.
18. H.-C.Jeung, S.Y.Rha, C.K.Im, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer. 2011;117(10):2050–2057.
19. D.J.Schwartzentruber, D.H.Lawson, J.M.Richards, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–2127.
20. European Organisation for Research and Treatment of Cancer. Available from: http://groups.eortc.be/qol/eortc-qlq-c30
21. Functional Assessment of Cancer. Available from: http://www.facit.org/FACITOrg/Questionnaires
22. EuroQol 5-dimensional scale. Available from: http://www.euroqol.org/about-eq-5d.html.
23. N.Black. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167.
24. O.Bylicki, H.K.Gan, F.Joly, et al. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26(1):231–237.
25. C.D.Amdal, A.-B.Jacobsen, M.G.Guren, et al. Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol Stockh Swed. 2013;52(4):679–690.
26. S.Ghimire, E.Kyung, E.Kim. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer. Lung. 2013;191(4):313–319.•• A review which searched for lung cancer trials in study registers. One similar finding of this review was the low number of studies planning to assess PRO in this field. The authors reported that HRQoL was a secondary end point in only 20% of phase II and III trials and that other PROs were rarely used.
27. G.Velikova, L.Booth, A.B.Smith, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(4):714–724.
28. A.Gilbert, D.Sebag-Montefiore, S.Davidson, et al. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol. 2015;136(3):429–439.
29. M.H.Levy, T.Smith, A.Alvarez-Perez, et al. Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw JNCCN. 2014;12(10):1379–1388.
30. G.Albers, M.A.Echteld, H.C.W.de Vet, et al. Evaluation of quality-of-life measures for use in palliative care: a systematic review. Palliat Med. 2010;24(1):17–37.
31. K.Mystakidou, E.Tsilika, E.Parpa, et al. The relationship between quality of life and levels of hopelessness and depression in palliative care. Depress Anxiety. 2008;25(9):730–736.
32. C.S.Cleeland, J.A.Sloan, D.Cella, et al. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the symptoms of cancer using patient-reported outcomes) multisymptom task force. Cancer. 2013;119(2):411–420.
33. S.Ahmed, R.A.Berzon, D.A.Revicki, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care. 1060–1070;50(12):2012.
34. Mapi Research Trust. Mapi research trust PROQOLID patient-reported outcome and quality of life instruments database. Available from: http://www.proqolid.org/
35. B.Wieseler, M.F.Kerekes, V.Vervoelgyi, et al. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ. 2012;344:d8141.